Athira Pharma to Present at H.C. Wainwright & Co. Global Life Sciences Conference

Rhea-AI Summary

Athira Pharma (NASDAQ: ATHA) will present a corporate overview at the H.C. Wainwright & Co. Global Life Sciences Conference. Leen Kawas, Ph.D., President and CEO, will lead the pre-recorded presentation available at 7:00 am ET on March 9, 2021. The presentation can be accessed on-demand through the Athira website, with an archived replay available for 90 days post-event. Athira focuses on developing small molecules to restore neuronal health, targeting Alzheimer’s and Parkinson’s dementia with its lead candidate, ATH-1017.

News Market Reaction – ATHA

-2.57%

-2.57% Session move

In the trading session that priced this news, ATHA declined 2.57%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOTHELL, Wash., March 02, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Leen Kawas, Ph.D., President and Chief Executive Officer, will present a corporate overview during the H.C. Wainwright & Co. Global Life Sciences Conference. A pre-recorded presentation will be available for on-demand viewing beginning at 7:00 am ET on Tuesday, March 9, 2021.

A webcast of the presentation will also be available on the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations. An archived replay of the webcast will be available for approximately 90 days following the event.

About Athira Pharma, Inc.
Athira, headquartered in Seattle, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. We aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, ATH-1017, a novel small molecule for Alzheimer’s and Parkinson’s dementia. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn and @athirapharma on Twitter and Instagram.

Investor & Media Contact:
Julie Rathbun
Athira Pharma
Julie.rathbun@athira.com
206-769-9219

FAQ

What is the date for Athira's presentation at the H.C. Wainwright Conference?

Athira will present on March 9, 2021, beginning at 7:00 am ET.

Who is presenting at the H.C. Wainwright Conference for Athira?

Leen Kawas, Ph.D., President and CEO of Athira, will present.

How can I watch Athira's presentation from the conference?

The presentation will be available for on-demand viewing on Athira's website.

What is the focus of Athira Pharma's research?

Athira focuses on developing small molecules to restore neuronal health and combat neurodegeneration.

What is Athira's lead therapeutic candidate?

Athira's lead candidate is ATH-1017, targeting Alzheimer’s and Parkinson’s dementia.